Vanda Pharmaceuticals Inc. (VNDA) said that the U.S. Food and Drug Administration has approved Fanapt (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
VNDA closed Tuesday's regular trading at $3.91 down $0.21 or 5.10%. But in the after-hours trading, the stock up $1.19 or 30.43%.
Fanapt is an atypical antipsychotic agent that has been used for the acute treatment of patients with schizophrenia since its FDA approval in 2009.
Bipolar disorder is a serious, highly prevalent psychiatric chronic condition affecting approximately 2.8% of the U.S. adult population, with 83% of them classified as severe. Bipolar disorder is a group of disorders that are characterized by periods of elevated mood alternating with periods of depressed mood.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.